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Background
Etanercept has approval for use in children with polyartic-
ular juvenile rheumatoid arthritis (JRA). Here we evaluate
the safety of etanercept in children with polyarticular or
systemic JRA.
Methods
This 3-year, open-label, non-randomized registry
included patients age 2–18, with a diagnosis of polyartic-
ular or systemic JRA. Patients treated with methotrexate
(MTX), etanercept (ETN), or methotrexate/etanercept in
combination (MTX/ETN) were eligible. Co-administra-
tion of non-biologic DMARDs was allowed. MTX was
administered at 0.3 to 1 mg/kg/wk and etanercept was
administered at 0.4 mg/kg (max 25 mg) twice weekly or
0.8 mg/kg (max 50 mg) weekly.
Results
602 patients enrolled; 198 received MTX, 105 received
ETN, and 299 received MTX/ETN. A total of 33%, 31%,
and 35% of patients have completed the 3-year registry for
a total of 388, 210, and 610 subject-years of exposure for
the MTX, ETN, and MTX/ETN groups, respectively. In the
MTX, ETN, and MTX/ETN groups, 18%, 8%, and 19% dis-
continued due to insufficient therapeutic effect while 2%,
2%, and 0.3% discontinued due to adverse events. The
rates of serious adverse events and medically important
infections per 100 patient-years were 4.4, 7.6, 5.7 and 1.3,
1.9, and 2.1 for patients receiving MTX, ETN, or MTX/
ETN. One case of lupus (MTX) and 2 cases of sepsis (ETN
and MTX/ETN) were reported. No cases of lymphoma,
malignancy, tuberculosis, or death were reported.
Conclusion
These data suggest etanercept is safe as a long-term, con-
tinuous therapy for treatment of JRA.
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